Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Genomma Lab InternacionalB de CV's accounts receivables for the quarter that ended in Mar. 2026 was MXN5,255 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Genomma Lab InternacionalB de CV's Days Sales Outstanding for the quarter that ended in Mar. 2026 was 114.42.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Genomma Lab InternacionalB de CV's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN-5.49.
Genomma Lab InternacionalB de CV Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Genomma Lab InternacionalB de CV's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Genomma Lab InternacionalB de CV's accounts receivable are only considered to be worth 75% of book value:
Genomma Lab InternacionalB de CV's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Genomma Lab InternacionalB de CV Accounts Receivable Related Terms
Genomma Lab InternacionalB de CV Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Accounts Receivable Chart
What does a Accounts Receivable of MXN5,255 Mil mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Accounts Receivable of MXN5,255 Mil as of Mar. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Accounts Receivable too high?
Genomma Lab InternacionalB de CV's current Accounts Receivable is MXN5,255 Mil. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Accounts Receivable compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Accounts Receivable of MXN5,255 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Drug Manufacturers company?
A good Accounts Receivable depends on the Drug Manufacturers industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Accounts Receivable is MXN5,255 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.67, compared to a current price of MXN15.33 — trading 13.2% below its estimated fair value. The current Accounts Receivable is MXN5,255 Mil. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Accounts Receivable is MXN5,255 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.33 is trading 13.2% below its estimated GF Value™ of MXN17.67.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Accounts Receivable: MXN5,255 Mil
GF Value™: MXN17.67 vs. price of MXN15.33 (13.2% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
